机构：[1]Department of Breast Surgery, The Third Hospital of Nanchang, China Jiangxi Province Key Laboratory for Breast Diseases,Nanchang, Jiangxi, P.R. China[2]Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, P.R. China[3]Fudan University Cancer Institute, Shanghai Cancer Center,Fudan University, Shanghai, P.R. China[4]Department of Oncology, Shanghai Medical College,Fudan University, Shanghai, P.R. China[5]Cancer Center, Traditional Chinese Medicine-Integrated Hospital,Southern Medical University, Guangzhou, Guangdong, P.R. China[6]Institutes of Biomedical Science, Fudan University,Shanghai, P.R. China[7]Department of General Surgery, Affiliated Union Hospital of Fujian Medical University,Union Clinical School, Fujian Medical University, Fujian, P.R. China[8]Department of Medical Oncology,Shanghai Cancer Center, Shanghai, P.R. China[9]Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, P.R. China[10]Department of Urology,Shanghai Tenth People's Hospital, Tongji University, Shanghai, P.R. China
Breast cancer is the most prevalent type of cancer among women. CD59, a membrane complement regulatory protein, has been demonstrated to be overexpressed in most solid tumors, where it facilitates tumor cell escape from complement surveillance. However, the role of CD59 in breast cancer growth and clinical prognosis is not fully revealed. To investigate the role of CD59 in breast cancer growth and prognostic significance, we knocked down CD59 in a breast cancer cell line that is highly metastatic to the lungs, MDA-MB‑231-HM. Cell growth was measured in vitro and in vivo using a xenograft model. In addition, clinical data on a cohort of 120 patients with or without lung metastasis was analyzed based on CD59 expression, which was detected by immunohistochemistry. Knockdown of CD59 significantly inhibited MDA-MB‑231-HM cell growth both in vitro and in vivo. An analysis of clinical data on 120 patients revealed that patients with CD59 overexpression may have a worse prognosis. CD59 may therefore be a prognostic biomarker for poor outcome in breast cancer patients.
基金：
National Natural Science Foundation of China (81201531), the 2012
Shanghai Committee of Science and Technology Funds
(12ZR1406200, 12DZ2260100 and 12140901502), and the
Shanghai Committee of Science and Technology Fund for
2013, Qimingxing Project (11QA1401400 to X. Hu).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2015]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Breast Surgery, The Third Hospital of Nanchang, China Jiangxi Province Key Laboratory for Breast Diseases,Nanchang, Jiangxi, P.R. China[2]Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, P.R. China[3]Fudan University Cancer Institute, Shanghai Cancer Center,Fudan University, Shanghai, P.R. China[4]Department of Oncology, Shanghai Medical College,Fudan University, Shanghai, P.R. China[5]Cancer Center, Traditional Chinese Medicine-Integrated Hospital,Southern Medical University, Guangzhou, Guangdong, P.R. China
共同第一作者：
通讯作者：
通讯机构：[2]Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, P.R. China[3]Fudan University Cancer Institute, Shanghai Cancer Center,Fudan University, Shanghai, P.R. China[4]Department of Oncology, Shanghai Medical College,Fudan University, Shanghai, P.R. China[5]Cancer Center, Traditional Chinese Medicine-Integrated Hospital,Southern Medical University, Guangzhou, Guangdong, P.R. China[6]Institutes of Biomedical Science, Fudan University,Shanghai, P.R. China[*1]Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Shanghai Cancer Center, Fudan University, 270 Dong-An Road, Shanghai 200032, P.R. China[*2]Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, 1838 Guangzhou N Avenue, Baiyun, Guangzhou, Guangdong 510515, P.R. China
推荐引用方式(GB/T 7714)：
Ouyang Qianwen,Zhang Long,Jiang Yizhou,et al.The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer.[J].International journal of oncology.2016,48(5):2015-24.doi:10.3892/ijo.2016.3408.
APA：
Ouyang Qianwen,Zhang Long,Jiang Yizhou,Ni Xiaojian,Chen Sheng...&Shao Zhiming.(2016).The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer..International journal of oncology,48,(5)
MLA：
Ouyang Qianwen,et al."The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer.".International journal of oncology 48..5(2016):2015-24
